Clinical efficacy of atezolizumab plus bevacizumab for first‐line treatment of unresectable hepatocellular carcinoma

Advanced hepatocellular carcinoma (HCC) has limited treatment options and poor prognosis. Only two tyrosine kinase inhibitors have been approved as single agents for firstline treatment over the last decade. In 2020, atezolizumab combined with bevacizumab was approved for first‐line treatment of advanced HCC. As the first brand‐new therapy to surpass sorafenib, atezolizumab combined with bevacizumab showed good safety and life quality in patients. The authors introduced the diagnosis and treatment of a China Liver Cancer Staging Ⅲ b HCC patient receiving atezolizumab combined with bevacizumab, in order to provide references for patient management